

Current Understanding of the Neurobiology and Longitudinal Course of Geriatric Depression

Sara L. Weisenbach · Anand Kumar

Published online: 16 July 2014
© Springer Science+Business Media New York 2014

Abstract Late life depression is a complex disease associated with a number of contributing neurobiological factors, including cerebrovascular disease, neurodegeneration, and inflammation, which also contribute to its longitudinal prognosis and course. These factors create a context in which the brain is more vulnerable to the impact of stress, and thus, to depression. At the same time, some individuals are protected from late life depression and its consequences, even in the face of neurobiological vulnerability, through benefitting from one or more attributes associated with resilience, including social support, engagement in physical and cognitive activities, and brain reserve. Enhanced understanding of how neurobiological and environmental factors interact in predicting vulnerability and resilience is needed to predict onset and course of depression in late life and develop more effective interventions.

Keywords Late life depression · Vascular · Neurodegenerative · Inflammation · Resilience

Support for this work comes from a Level-2 Career Development Award from the Department of Veterans Affairs, Rehabilitation Research & Development to SLW.

This article is part of the Topical Collection on *Geriatric Disorders*

S. L. Weisenbach (✉) · A. Kumar
Department of Psychiatry, University of Illinois at Chicago, 1747 W.
Roosevelt Rd., Suite 155, Chicago, IL 60607, USA
e-mail: sweisenbach@psych.uic.edu

A. Kumar
e-mail: akumar@psych.uic.edu

S. L. Weisenbach
Jesse Brown VA Medical Center, Research & Development Program,
Chicago, IL, USA

Introduction

Late-life depression (LLD; defined as depression occurring in individuals age 65 or older, and distinct from late onset depression, which is a subtype of depression with onset after the age of 65) has been associated with high incidence of chronic illness, cognitive dysfunction, disability, and poor prognosis [1–5]. There has been a great deal of interest in understanding the neurobiological and psychosocial contributions to onset and maintenance of depression and depressive symptoms in older adults, in an attempt to identify more effective treatments and prevention strategies. In this paper we will begin by describing three plausible neurobiological avenues to onset and maintenance of LLD that have gained traction in the literature, including vascular, neurodegenerative, and inflammatory mechanisms. It is important to consider that, while described separately, these pathways likely interact in a dynamic fashion, and may overlap considerably in a given individual. Alexopoulos [6] proposes a model in which factors contributing to LLD be separated into “mediating mechanisms” (e.g., hypometabolism of dorsal cortical regions and hypermetabolism of ventral limbic regions), “predisposing brain abnormalities” (e.g., abnormalities in frontostriatal and limbic circuitry, heredity and psychological vulnerability), and “etiological contributors” (e.g., age-related brain changes, disease-related changes, and allostatic response to adversity). We urge the reader to consider this model in our discussion of plausible mechanisms of LLD. For example, vascular changes may be an etiological contributor, occurring as a result of disease-related changes, such as hypertension or cardiovascular disease. These vascular changes may then predispose to disruption and abnormal metabolism in frontostriatal regions [7, 8]. Under the umbrella of this model, one or more of these aforementioned factors creates a context in which the brain is more vulnerable to the impact of stressors. In the second section of the manuscript, we discuss factors that

have been shown to confer resilience to affective and cognitive changes, even in the face of vulnerability, including psychosocial factors, lifestyle factors, and brain reserve. We propose a model in which factors contributing to depression in late life can create an increasingly vulnerable brain, but which can be buffered by factors associated with resiliency (see Fig. 1).

Three Plausible Mechanisms of Depression in Late Life

Vascular

It has been recognized for some time [9, 10] that individuals with vascular risk factors, including hypertension, diabetes, atherosclerosis, and/or history of transient ischemic attacks or surgery for vascular disease are at greater risk for depression than those not experiencing vascular risk factors. Prominent symptoms of LLD, including cognitive deficits, anhedonia, psychomotor retardation, poor insight, and functional disability are similar to what might be anticipated from lesions to striato-pallido-thalamo-cortical pathways [11–14]. The vascular depression hypothesis states that “cerebrovascular disease may predispose, precipitate, or perpetuate some geriatric depressive syndromes” [15, p. 915]. The evidence supporting the vascular depression hypothesis is substantial, including clinical, behavioral, and structural and functional neuroimaging studies. For a more complete review of supporting evidence, we refer the interested reader to Taylor and colleagues [16••]. Here, we focus on the mechanisms underlying the relationship between vascular risk factors and depression, including disconnection and hypoperfusion, as thoroughly detailed in [16••].

Disconnection When vasculature that serves cerebral areas important for cognition and affective functioning is compromised, it can disrupt neural connections in and between these regions and impact behavior. There is evidence that cognitive performance and affective functioning are negatively impacted when specific fiber tracts and neural circuits are damaged, [12]. For example, a recent study by Lamar and colleagues [17•] found that lower fractional anisotropy (FA) in the uncinate fasciculus predicted poorer performance on a measure of executive functioning among 26 patients with LLD. Also, in a study of 145 healthy and cognitively impaired older adults, Smith and colleagues [18] measured global and focal white matter hyperintensity (WMH) volume, and found that WMH in bilateral temporal-occipital, right parietal periventricular, and left anterior limb of the internal capsule were associated with episodic memory performance, while WMH in bilateral inferior frontal, bilateral temporal-occipital, right parietal periventricular, and bilateral anterior limb of the internal capsule were predictive of executive function performance, independent of total white matter volume. Finally, Dalby and

colleagues [19] demonstrated a positive relationship between depression severity and fiber tracts intersected by white matter lesions in the left superior longitudinal fasciculus and the right uncinate fasciculus among 22 patients with LLD.


Hypoperfusion Another potential mechanism to account for the relationship between cerebral vascular pathology and depression is reduced perfusion of blood to key brain regions integral to affective and cognitive processing. One such measure of cerebral hemodynamics is that of carotid intima-media thickness (IMT), which encompasses the innermost two layers of the arterial wall, is a reflection of atherosclerosis and vascular disease risk [20], and correlates strongly with atherosclerosis itself [21]. Studies have shown IMT to be higher among older adults with LLD (relative to comparisons), and to correlate with WMH among patients with LLD [22]. IMT is also associated with later age of depression onset [23], and is positively associated with non-response to antidepressants [24].

Arterial endothelial function is another way to assess vascular function and pathology. Vascular endothelium are the thin layer of cells that line the inner surface of blood vessels and form an interface between blood and the rest of the vessel wall. They are involved in a number of important functions, including the inflammatory response and control of blood pressure [25]. While it is not possible to directly assess the functioning of endothelia within the brain, it is often reflected in gluteal fat [26]. A study of older patients with LLD found that endothelial function was poorer in depressed relative to (NDC) comparisons, independent of response to antidepressant therapy [24]. Another study of LLD patients found reduction in the dilation response to acetylcholine (a vasodilator) in precontracted small arteries [27, 28]. Given that this did not correlate with the severity or volume of WMH [28], Taylor and colleagues [16••] suggested that WMH may actually be an endpoint to perfusion deficits, which do not need to cause ischemia to impact brain functioning.

Blood flow velocity using cerebral transcranial Doppler ultrasound is also capable of reflecting vascular function. Among a large sample of NDC older people, lower peak-systolic, end-diastolic, and average blood flow velocities at baseline were associated with higher depression symptom severity at the follow-up visit approximately 3–6 years later. Moreover, mean blood flow velocity and decreased baseline vasomotor reactivity, which compensates for maintaining cerebral blood flow during mental activity, predicted incident depressive symptoms during the span of the follow-up period [29•].

In summary, there is wide support for the suggestion that for at least a subset of individuals with LLD, vascular changes, including hypoperfusion of and disrupted connection between regions relevant to cognition and affective regulation are one mechanism of depression in late life and its associated symptoms.

Fig. 1 Factors contributing to depression in late life, including cerebrovascular disease, neurodegeneration, and chronic inflammation can create an increasingly vulnerable brain, that is prone to depression, especially in the face of stress. Factors associated with resilience, including social support and participation, physical and cognitive engagement, and brain reserve, can buffer even vulnerable brains from the development of depression



Neurodegenerative

Epidemiology There have been many studies investigating depression as a prodromal symptom and risk factor of neurodegenerative diseases, such as Alzheimer’s disease (AD; for review, [30]), with mixed findings. A systematic review, meta-analysis, and metaregression analysis of prospective studies of risk of developing dementia among individuals with and without depression concluded a pooled odds ratio (OR) of 2.03, with 1.73 for case-control and 1.90 for cohort studies. Interestingly, the longer the interval between the diagnosis of depression and development of dementia, the higher was the risk of developing AD, suggesting that AD is a risk factor, as opposed to a prodromal state of AD. Similarly, a more recent systematic review and meta-analysis in 23 prospective population-based studies found that LLD was associated with significantly increased risk for all-cause dementia (1.85 OR), and clinical diagnoses of Alzheimer’s disease (1.65 OR), and vascular dementia [31••].

Structural Neuroimaging Supporting a neurodegenerative path to AD, there have been a multitude of studies demonstrating cerebral atrophy in LLD patients, in regions that play a critical role in memory, executive functioning, and other cognitive processes known to decline in early AD [32, 33, 34••, 35]. Interestingly, among 334 participants with mild cognitive impairment (MCI) enrolled in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) study, depression symptom severity was associated with reduced entorhinal cortex thickness at baseline, as well as accelerated atrophy over an average of 30.5-month follow-up [36•]. It is important to note that neurodegenerative and vascular changes, while both present in those with LLD, may be independent processes. A study by Kumar and colleagues [33] found smaller frontal lobe volumes and larger whole brain lesion volumes among those with LLD, relative to NDCs. After controlling for medical comorbidities, however, the relationship between whole brain lesion

volume and LLD was reduced to non-significance, while lower frontal lobe volume continued to be associated with LLD. Moreover, frontal lobe volume and brain lesion volume were not correlated. Together these findings suggest that vascular and neurodegenerative processes may be autonomous pathways contributing to LLD, independent of one another in the context of LLD.

Neuropathology Given structural imaging findings and results from epidemiological community studies suggesting an increased risk of AD among those with depression, there has been work investigating the presence of neuropathological features of neurodegenerative disease in post-mortem-brain tissue, although these studies are limited in number and sample sizes are small. In the first study to characterize neuropathologic diagnoses in a group of LLD patients (n=10), Sweet and colleagues [37] found that of the seven patients with dementia at death, six met neuropathologic criteria for AD, which was similar to the rate of AD in patients with dementia without a history of mood disorder. Among the six LLD patients with dementia, all had comorbid Dementia with Lewy Bodies (DLB) or cerebrovascular disease. Other studies of post-mortem brain in LLD have failed to show an association between the presence of depression prior to death and Alzheimer’s pathology [38, 39], although these studies excluded individuals with dementia, eliminating the group most likely to show such neuropathological changes. Interestingly, in one of these studies, individuals with history of depression were more likely than never-depressed comparisons to show neuropathology associated with DLB [38], while in the other study, those with history of depression had more atheromatous disease [39]. Taking a different approach, Rapp and colleagues [40] found that AD patients with a history of depression had higher levels of plaque and tangle formation than did AD patients with no history of depression. While studies of neuropathology in LLD have begun to provide some support for findings of increased risk of dementia in larger,

community-based, epidemiological studies, methodological limitations preclude drawing any conclusions at the current time regarding the actual prevalence of neuropathological features in the brains of patients with LLD or history of depression.

Positron Emission Tomography (PET) Newer imaging techniques, such as PET scanning, have allowed investigators to study, in-vivo, the presence of neuropathological features of Alzheimer's disease in living humans. The first study, by Butters and colleagues [41] used Pittsburgh Compound-B ($[^{11}\text{C}]\text{PiB}$) to visualize β -amyloid plaque accumulation in the brains of eight individuals with remitted major depressive disorder (MDD; six with comorbid MCI) compared to eight never-depressed elders (none with MCI). Results demonstrated that one-half of subjects with comorbid MCI and depression history had $[^{11}\text{C}]\text{PiB}$ retention in the range of what is typically seen in AD, while the other half had values that were intermediate to those typically observed in healthy comparison and AD subjects. The two non-MCI patients demonstrated values that were similar to healthy comparisons. A second study by Kumar and colleagues [42] used $[^{18}\text{F}]\text{FDDNP}$ to image amyloid and tau in the brains of 20 LLD patients (one with comorbid MCI) and 19 never-depressed comparisons. They found greater $[^{18}\text{F}]\text{FDDNP}$ binding in the posterior cingulate and lateral temporal regions in the LLD group. Similarly, Wu and colleagues [43] studied 25 LLD and 11 comparison subjects (none with comorbid MCI), and found increased ^{18}F -Florbetapir (AV-45/Amyvid) binding (to amyloid plaques) among LLD patients. In contrast, another group found no association between previous depressive episodes and increased $[^{11}\text{C}]\text{PiB}$ binding [44]. It is notable that individuals in this latter study could not have had depression for at least six years prior to enrollment in the study, and thus may represent a group of LLD individuals who are at less risk of going on to develop cognitive decline and/or dementia.

Plasma Studies The aforementioned PET studies provide some evidence that neuropathological features of AD are more prevalent in the brains of individuals with LLD relative to NDC individuals, though are limited by small sample sizes and heterogeneous methodologies, with some studies including patients with MCI, others including a few with MCI, and still others excluding those with MCI altogether. Some groups have chosen to use plasma and/or CSF to quantify β -amyloid. Changes in plasma $\text{A}\beta_{40}$, $\text{A}\beta_{42}$, and $\text{A}\beta_{42}/40$ ratios may be linked to increased risk for incident AD [45, 46], while reduced levels of CSF $\text{A}\beta_{42}$ are associated with $\text{A}\beta$ deposition in brain senile plaques [47]. In a study of 48 LLD patients relative to 35 NDC, elevated levels of plasma $\text{A}\beta_{42}$ and $\text{A}\beta_{42}/40$ ratios were found in the LLD group, and this was associated with greater severity of white matter

hyperintensity burden, but not age of onset of first depressive episode [48]. A review by Osorio and colleagues [49] concluded, however, that the relationship of LLD with plasma $\text{A}\beta$ levels is equivocal, with some studies demonstrating higher levels of $\text{A}\beta$ in the LLD group, relative to the NDC group (or positive associations between $\text{A}\beta$ and depressive symptoms), some finding the opposite relationship, and others finding no differences. At the same time, baseline $\text{A}\beta_{42}$ [50] and $\text{A}\beta_{42}/40$ ratios [51] have been shown to be predictive of new onset of future depressive symptoms, although this may be specific to ApoE4 carriers [51]. The authors cite between-study methodological differences, heterogeneity of LLD, in addition to disease-stage dependent differences in the trajectory of $\text{A}\beta$ changes as possible explanations for disparate findings. [49].

Cerebrospinal Fluid Studies CSF markers of Alzheimer's disease are more reliable indicators than plasma studies of CNS amyloid deposition [48]. In one study, Pomara and colleagues [52] detected significantly lower levels of $\text{A}\beta_{42}$ in a group of 27 cognitively-intact women and men with LLD, relative to the NDC group. In contrast, Gudmundsson and colleagues [53] found higher levels of CSF $\text{A}\beta_{42}$ among a small group of women with depression ($n=14$), relative to those without LLD. Importantly, the former study included individuals with more chronic forms of depression, whereas the latter study were community volunteers who may have had more acute forms of depression [52]. Importantly, none of the three studies of CSF markers in MDD to date have detected significant between group differences in $\text{A}\beta_{40}$, total tau, or phosphorylated tau, which are also markers of Alzheimer's disease [53, 54], suggesting that the absence of these markers may distinguish LLD without AD from the comorbid condition. However, tau pathology may be a downstream effect of amyloid beta deposition [55], so may not be particularly useful as a biomarker of early AD.

Given the association between depression and risk for dementia, in addition to mixed evidence of increased amyloid burden in older adults with history of depression, there has been interest in the mechanisms underlying these relationships. One theory that has been proposed is HPA-axis dysfunction, known to be associated with depression [56] and hippocampal volume loss [57]. This theory is supported by studies of animal models. In a mouse model, stress-level glucocorticoid administration was associated with increased amyloid- β and tau-pathology [58]. Further, acute stress (i.e., three months of isolation) has been shown to increase levels of amyloid in the brain [59, 60]. Follow-up study suggested that the relationship between stress and amyloid deposition may be mediated by increased corticosterone levels [59].

In summary, large-scale studies suggest that depression is associated with increased risk of dementia, and some studies have demonstrated neuropathological changes associated with neurodegenerative diseases in LLD in autopsied human brain, in-vivo imaging, and studies of CSF and plasma. Animal studies suggest that HPA-axis dysfunction may be one mechanism by which LLD is associated with neurodegenerative changes.

Inflammatory Processes

Plasma Studies Inflammatory explanations for depression across the lifespan have gained a great deal of traction in recent years. In a seminal review, Alexopoulos and Morimoto [61] suggest that inflammatory processes related to aging and disease may provoke neural and/or metabolic changes that predispose to the development of depression in late life. A multitude of studies have demonstrated an association between levels of peripheral pro-inflammatory cytokines and depressive symptoms in older people [62•, 63–71]. While a variety of pro-inflammatory markers have been studied, interleukin-6 (IL -6) has been most reliably associated with depressive symptoms after possible confounding variables, such as age chronic disease, cognitive functioning, and anti-depressants have been covaried. There may be an interaction of inflammatory and vascular processes predisposing to LLD, as higher levels of IL-6 and C-reactive protein have been associated with greater white matter pathology [72, 73•, 74, 75]. IL-6 levels have also been negatively associated with memory performance in depressed and NDC older adults [76•]. Pro-inflammatory cytokines also impact monoamine neurotransmitter pathways [77–79], resulting in reduced tryptophan and serotonin synthesis [77, 80]. In addition, they disrupt function of glucocorticoid receptors and decrease hippocampal neurotrophic support [81]. Alexopoulos and Morimoto [61] propose that dramatic and prolonged CNS immune response can impact emotional and cognitive network functions that are relevant to depression, and can contribute to the etiology of at least some LLD syndromes.

Interestingly, chronic inflammation has also been associated with increased risk of vascular dementia and AD, with an increased incidence of vascular events and smaller hippocampal volume. Leonard [82] hypothesized that the progression of depression to dementia may be mediated by the activation of macrophages and microglia in the brain, linked to chronic inflammation. In their review of the literature, Hermida and colleagues [83] propose that individuals with LLD and activation of the inflammatory pathway may be most vulnerable to vascular events, the amyloid cascade, or both processes.

Resilience

The three neurobiological processes reviewed (vascular, neurodegenerative, and inflammatory), likely increase the vulnerability of the brain to the adverse impact of stressors, both psychosocial and physiological. Yet, there are individuals who, even with the accumulation of apparent neurobiological predisposition, do not develop depression or cognitive decline. For example, in one study, 40 % of non-depressed, cognitively normal older adults displayed the presence of at least one AD-sensitive biomarker (i.e., hippocampal volume, gray matter thickness, and glucose tolerance) [84••]. Findings such as these suggest moderating variables that might increase or decrease the likelihood of cognitive decline and depression, even in the face of neurobiological vulnerability.

Psychosocial Factors There is a large literature on the protective effect of psychosocial variables to cognitive and emotional health in aging. In one study of 234 older people residing in two independent living facilities, scores on a depression symptom severity rating scale were significantly predicted by three psychosocial-oriented variables, including fewer neighbor visitors, less participation in organized social activities, and less church attendance [85]. A second study of 889 community-dwelling individuals found that lack of contact with friends was a significant risk factor for the development of depression over one year, and maintenance of depressive symptoms was predicted by low levels of social support and social participation [86]. Social support has also been demonstrated to buffer against the effects of disability on depression in late life [86, 87].

Lifestyle Factors Physical and cognitive engagement have been associated with reduced risk for AD and cognitive decline in a multitude of studies, and are now widely cited as potentially modifiable risk factors of dementia [88]. In a study of 92 cognitively normal older adults, those with higher lifetime cognitive activity and higher current physical activity had fewer white matter lesions (WML). In turn, WML were associated with a composite measure of neural integrity and better cognitive functioning. Additionally, less A β burden buffered against the negative impact of poor neural integrity on cognitive functioning. The authors concluded that cognitive and physical activities may protect against cerebrovascular and A β pathology, and potentially the development of dementia, in late life [89•]. Depressive symptoms were not measured in this study, though volunteers reported no current psychiatric symptoms.

Physical activity has been demonstrated as an effective intervention for depression in older adults in at least nine studies [90], although it is not yet clear from the literature whether lifetime physical activity prevents the onset of depressive symptoms. Conceptually, however, given the

relationship of depression with cerebrovascular pathology and overall neural integrity, one would expect that lifetime physical activity would also be protective of depression onset in late life.

Brain Reserve Brain reserve theory [91] hypothesizes that individuals with high brain reserve, typically defined by education, which is associated with greater synaptic density, are less likely to exhibit behavior associated with dementia when faced with neurological insult. There has been a great deal of study on the effect of brain reserve on delaying clinically relevant cognitive deficits in dementia [92, 93, 94]. There has been little study, on the other hand, as to the impact of cognitive reserve on the expression of depressive symptomatology. An interesting study using the Health and Retirement Survey, that includes 1355 stroke-free women greater than 80 years of age studied over six years found that level of education (i.e., brain reserve), and the interaction of cerebrovascular burden (by self-report and smoking history) interacted with level of education in negatively predicting depressive symptoms at baseline. While the protective effect of brain reserve diminished over the study period, these results suggest that brain reserve may buffer against the effects of cerebrovascular burden on depressive symptoms, and should be replicated in other studies that include men [95].

Conclusions

LLD is a complex, heterogeneous disease with a multitude of dynamic and likely overlapping etiologies. Vascular, neurodegenerative, and inflammatory factors have gained the most traction in the literature as to possible mechanisms by which depression in late life develops and persists. However, this is certainly not an exhaustive list, and there are likely other less studied or never studied factors that also contribute. Psychosocial factors, such as social support, as well as lifestyle choices (e.g., physical activity), and cognitive reserve may protect against the effects of adverse neurobiological events in what would otherwise be a brain vulnerable to depression and cognitive decline. Future research would benefit from measuring multimodal neurobiological and environmental factors to better understand how they interact in predicting onset and course of depression in late life.

Compliance with Ethics Guidelines

Conflict of Interest Anand Kumar declares no conflict of interest.

Sara L. Weisenbach has received a grant from the Department of Veterans Affairs (Career Development Award)

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Bruce ML, Seeman TE, Merrill SS, Blazer DG. The impact of depressive symptomatology on physical disability: MacArthur Studies of Successful Aging. *Am J Public Health*. 1994;84:1796–9.
2. Bruce ML. Depression and disability in late life: directions for future research. *Am J Geriatr Psychiatry*. 2001;9:102–12.
3. Gallo JJ, Bogner HR, Morales KH, et al. The effect of a primary care practice-based depression intervention on mortality in older adults: a randomized trial. *Ann Intern Med*. 2007;146:689–98.
4. Sheeran T, Brown EL, Nassisi P, Bruce ML. Does depression predict falls among home health patients? Using a clinical-research partnership to improve the quality of geriatric care. *Home Healthc Nurse*. 2004;22:384–9.
5. Voaklander DC, Rowe BH, Dryden DM, et al. Medical illness, medication use and suicide in seniors: a population-based case-control study. *J Epidemiol Community Health*. 2008;62:138–46.
6. Alexopoulos GS. Depression in the elderly. *Lancet*. 2005;365:1961–70.
7. Aizenstein HJ, Butters MA, Figurski JL, et al. Prefrontal and striatal activation during sequence learning in geriatric depression. *Biol Psychiatry*. 2005;58:290–6.
8. Aizenstein HJ, Butters MA, Wu M, et al. Altered functioning of the executive control circuit in late-life depression: episodic and persistent phenomena. *Am J Geriatr Psychiatry*. 2009;17:30–42.
9. Post F. The significance of affective disorders in old age. London: Institute of Psychiatry; 1962. Maudsley Monograph.
10. Post F, Schulman K. New views on old age affective disorder. In: Aire T, editor. *Recent advances in psychogeriatrics*. New York: Churchill Livingstone Inc; 1985. p. 119–40.
11. Alexopoulos GS. “The depression-executive dysfunction syndrome of late life”: a specific target for D3 agonists? *Am J Geriatr Psychiatry*. 2001;9:22–9.
12. Alexopoulos GS. Frontostriatal and limbic dysfunction in late-life depression. *Am J Geriatr Psychiatry*. 2002;10:687–95.
13. Krishnan KR, Hays JC, Blazer DG. MRI-defined vascular depression. *Am J Psychiatry*. 1997;154:497–501.
14. Krishnan KR, Taylor WD, McQuoid DR, et al. Clinical characteristics of magnetic resonance imaging-defined subcortical ischemic depression. *Biol Psychiatry*. 2004;55:390–7.
15. Alexopoulos GS, Meyers BS, Young RC, et al. ‘Vascular depression’ hypothesis. *Arch Gen Psychiatry*. 1997;54:915–22.
16. Taylor WD, Aizenstein HJ, Alexopoulos GS. The vascular depression hypothesis: mechanisms linking vascular disease with depression. *Mol Psychiatry*. 2013;18:963–74. *This seminal review of the vascular depression literature proposes three mechanisms mediating the relationship between vascular disease and depression in late life, including disconnection, hypoperfusion, and inflammation.*
17. Lamar M, Charlton RA, Ajilore O, et al. Prefrontal vulnerabilities and whole brain connectivity in aging and depression. *Neuropsychologia*. 2013;51:1463–70. *Healthy older adults exhibited a significant relationship between white matter network vulnerability as measured using diffusion tensor imaging fractional*

- anisotropy (FA) and performance on the Object Alteration Task. This relationship was not present in older depressed individuals, in which a significant relationship was observed only in FA of the uncinate fasciculus and task performance. The authors conclude that whole brain impact of vulnerabilities in fronto-limbic networks associated with aging may be obscured in the context of disease, such as depression.*
18. Smith EE, Salat DH, Jeng J, et al. Correlations between MRI white matter lesion location and executive function and episodic memory. *Neurology*. 2011;76:1492–9.
 19. Dalby RB, Frandsen J, Chakravarty MM, et al. Depression severity is correlated to the integrity of white matter fiber tracts in late-onset major depression. *Psychiatry Res*. 2010;184:38–48.
 20. de Groot E, Hovingh GK, Wiegman A, et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. *Circulation*. 2004;109(23 Suppl 1):III33–8.
 21. Wong M, Edelstein J, Wollman J, Bond MG. Ultrasonic-pathological comparison of the human arterial wall. Verification of intima-media thickness. *Arterioscler Thromb*. 1993;13:482–6.
 22. Chen CS, Chen CC, Kuo YT, et al. Carotid intima-media thickness in late-onset major depressive disorder. *Int J Geriatr Psychiatry*. 2006;21:36–42.
 23. Smith PJ, Blumenthal JA, Babyak MA, et al. Intima-media thickness and age of first depressive episode. *Biol Psychol*. 2009;80:361–4.
 24. Paranthaman R, Greenstein A, Burns AS, et al. Relationship of endothelial function and atherosclerosis to treatment response in late-life depression. *Int J Geriatr Psychiatry*. 2012;27:967–73.
 25. Deanfield J, Donald A, Ferri C, et al. Endothelial function and dysfunction. Part I: methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. *J Hypertens*. 2005;23:7–17.
 26. Di Napoli M, Papa F. C-reactive protein and cerebral small-vessel disease: an opportunity to reassess small-vessel disease pathophysiology? *Circulation*. 2005;112:781–5.
 27. Greenstein AS, Paranthaman R, Burns A, et al. Cerebrovascular damage in late-life depression is associated with structural and functional abnormalities of subcutaneous small arteries. *Hypertension*. 2010;56:734–40.
 28. Paranthaman R, Greenstein AS, Burns AS, et al. Vascular function in older adults with depressive disorder. *Biol Psychiatry*. 2010;68:133–9.
 - 29.• Direk N, Koudstaal PJ, Hofman A, et al. Cerebral hemodynamics and incident depression: the Rotterdam Study. *Biol Psychiatry*. 2012;72:318–23. *In a large cohort of older adults from the Rotterdam Study, lower blood flow velocity (a proxy for cerebral metabolism), was associated with depressive symptoms and disorders. Reduced vasomotor activity (suggestive of cerebral microangiopathy), was associated with depressive disorders.*
 30. Byers AL, Yaffe K. Depression and risk of developing dementia. *Nat Rev Neurol*. 2011;7:323–31.
 - 31.•• Diniz BS, Butters MA, Albert SM, et al. Late-life depression and risk of vascular dementia and Alzheimer's disease: systematic review and meta-analysis of community-based cohort studies. *Br J Psychiatry*. 2013;202:329–35. *A meta-analysis of 23 studies to calculate the pooled risk of dementia in late life depression resulted in odds ratios of 1.85 for all cause dementia, 1.65 for Alzheimer's disease, and 2.52 for vascular dementia, respectively.*
 32. Geerlings MI, den Heijer T, Koudstaal PJ, et al. History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. *Neurology*. 2008;70:1258–64.
 33. Kumar A, Bilker W, Jin Z, Udupa J. Atrophy and high intensity lesions: complementary neurobiological mechanisms in late-life major depression. *Neuropsychopharmacology*. 2000;22:264–74.
 - 34.•• Sexton CE, Mackay CE, Ebmeier KP. A systematic review and meta-analysis of magnetic resonance imaging studies in late-life depression. *Am J Geriatr Psychiatry*. 2013;21:184–95. *A meta-analysis of 17 studies investigating gray matter volumes in late life depression found significantly lower volumes in hippocampus, orbitofrontal cortex, putamen, and thalamus among depressed relative to non-depressed comparison participants.*
 35. Steffens DC, Byrum CE, McQuoid DR, et al. Hippocampal volume in geriatric depression. *Biol Psychiatry*. 2000;48:301–9.
 - 36.• Zahodne LB, Gongvatana A, Cohen RA, Ott BR, Tremont G. Are apathy and depression independently associated with longitudinal trajectories of cortical atrophy in mild cognitive impairment? *Am J Geriatr Psychiatry*. 2013;21:1098–106. *Using a sample of 334 participants with Mild Cognitive Impairment (MCI) from the Alzheimer's Disease Neuroimaging Initiative Study, investigators found that depression was associated with less cortical thickness in the entorhinal cortex at baseline and greater atrophy over the study period (M = 30.5 months). Apathy was not predictive of cortical thickness in any region measured at baseline or over the study period. Findings suggest that in patients with MCI, depression may be a stronger predictor of longitudinal cortical atrophy than apathy.*
 37. Sweet RA, Hamilton RL, Butters MA, et al. Neuropathologic correlates of late-onset major depression. *Neuropsychopharmacology*. 2004;29:2242–50.
 38. Beekman AT. Neuropathological correlates of late-life depression. *Expert Rev Neurother*. 2011;11:947–9.
 39. Thomas AJ, Ferrier IN, Kalaria RN, et al. A neuropathological study of vascular factors in late-life depression. *J Neurol Neurosurg Psychiatry*. 2001;70:83–7.
 40. Rapp MA, Schnaider-Beerli M, Grossman HT, et al. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. *Arch Gen Psychiatry*. 2006;63:161–7.
 41. Butters MA, Klunk WE, Mathis CA, et al. Imaging Alzheimer pathology in late-life depression with PET and Pittsburgh Compound-B. *Alzheimer Dis Assoc Disord*. 2008;22:261–8.
 42. Kumar A, Kepe V, Barrio JR, et al. Protein binding in patients with late-life depression. *Arch Gen Psychiatry*. 2011;68:1143–50.
 43. Wu C, Pike VW, Wang Y. Amyloid imaging: from benchtop to bedside. *Curr Top Dev Biol*. 2005;70:171–213.
 - 44.• Madsen K, Hasselbalch BJ, Frederiksen KS, et al. Lack of association between prior depressive episodes and cerebral [11C]PiB binding. *Neurobiol Aging*. 2012;33:2334–42. *Older adults with remitted depression were equivalent to never-depressed comparisons in [11C]PiB binding, but did demonstrate more severe white matter lesions. There were no associations between PiB binding and number of depressive episodes, cognitive performance, or antidepressant treatment. The authors conclude that their findings suggest that history of depression may not be associated with development of Alzheimer's disease.*
 45. Pomara N, Willoughby LM, Sidtis JJ, Mehta PD. Selective reductions in plasma Abeta 1–42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. *Am J Geriatr Psychiatry*. 2005;13:914–7.
 46. Schupf N, Tang MX, Fukuyama H, et al. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. *Proc Natl Acad Sci*. 2008;105:14052–7.
 47. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. *Ann Neurol*. 2006;59:512–9.
 48. Pomara N, Doraiswamy PM, Willoughby LM, et al. Elevation in plasma Abeta42 in geriatric depression: a pilot study. *Neurochem Res*. 2006;31:341–9.
 49. Osorio RS, Gumb T, Pomara N. Soluble amyloid-beta levels and late-life depression. *Curr Pharm Des*. 2014;20:2547–54.
 50. Blasko I, Kemmler G, Jungwirth S, et al. Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease. *Am J Geriatr Psychiatry*. 2010;18:973–82.

51. Sun X, Steffens DC, Au R, et al. Amyloid-associated depression: a prodromal depression of Alzheimer disease? *Arch Gen Psychiatry*. 2008;65:542–50.
52. Pomara N, Bruno D, Sarreal AS, et al. Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. *Am J Psychiatry*. 2012;169:523–30. *In a sample of 47 non-demented older adults, CSF A β 42 levels were significantly lower and isoprostane levels were significantly higher among those with Major Depressive Disorder relative to the healthy comparison group. There were no group differences in measures of CSF tau. The authors conclude that the reduction in CSF amyloid beta levels in older adults with depression may be due to increased brain beta amyloid plaques or decreased soluble amyloid beta production.*
53. Gudmundsson P, Skoog I, Waern M, et al. The relationship between cerebrospinal fluid biomarkers and depression in elderly women. *Am J Geriatr Psychiatry*. 2007;15:832–8.
54. Buerger K, Zinkowski R, Teipel SJ, et al. Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. *Am J Psychiatry*. 2003;160:376–9.
55. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. *Trends Pharmacol Sci*. 1991;12:383–8.
56. Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. *Psychosom Med*. 2011;73:114–26.
57. Wolf OT, Convit A, de Leon MJ, et al. Basal hypothalamo-pituitary-adrenal axis activity and corticotropin feedback in young and older men: relationships to magnetic resonance imaging-derived hippocampus and cingulate gyrus volumes. *Neuroendocrinology*. 2002;75:241–9.
58. Green KN, Billings LM, Roozendaal B, et al. Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. *J Neurosci*. 2006;26:9047–56.
59. Dong H, Yuede CM, Yoo HS, et al. Corticosterone and related receptor expression are associated with increased beta-amyloid plaques in isolated Tg2576 mice. *Neuroscience*. 2008;155:154–63.
60. Kang JE, Cirrito JR, Dong H, et al. Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. *Proc Natl Acad Sci U S A*. 2007;104:10673–8.
61. Alexopoulos GS, Morimoto SS. The inflammation hypothesis in geriatric depression. *Int J Geriatr Psychiatry*. 2011;26:1109–18.
62. Baune BT, Smith E, Reppermund S, et al. Inflammatory biomarkers predict depressive, but not anxiety symptoms during aging: the prospective Sydney Memory and Aging Study. *Psychoneuroendocrinology*. 2012;37:1521–30. *Among 1037 non-demented community volunteers, IL-6 and IL-8 levels were associated with depressive symptoms at baseline. IL-8 levels were additionally associated with depressive symptoms at two-year follow-up and the onset of mild to moderate depression over two years. PAI-I was related to remitted depression, and there was no relationship with cytokine levels and anxiety symptoms.*
63. Bremner MA, Beekman AT, Deeg DJ, et al. Inflammatory markers in late-life depression: results from a population-based study. *J Affect Disord*. 2008;106:249–55.
64. Dentino AN, Pieper CF, Rao MK, et al. Association of interleukin-6 and other biologic variables with depression in older people living in the community. *J Am Geriatr Soc*. 1999;47:6–11.
65. Dimopoulos N, Piperi C, Psarra V, et al. Increased plasma levels of 8-iso-PGF2 α and IL-6 in an elderly population with depression. *Psychiatry Res*. 2008;161:59–66.
66. Forti P, Rietti E, Pisacane N, et al. Blood inflammatory proteins and risk of incident depression in the elderly. *Dement Geriatr Cogn Disord*. 2010;29:11–20.
67. Matheny ME, Miller RR, Shardell MD, et al. Inflammatory cytokine levels and depressive symptoms in older women in the year after hip fracture: findings from the Baltimore Hip Studies. *J Am Geriatr Soc*. 2011;59:2249–55.
68. Milaneschi Y, Corsi AM, Penninx BW, et al. Interleukin-1 receptor antagonist and incident depressive symptoms over 6 years in older persons: the InCHIANTI study. *Biol Psychiatry*. 2009;65:973–8.
69. Penninx BW, Kritchevsky SB, Yaffe K, et al. Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. *Biol Psychiatry*. 2003;54:566–72.
70. Naude PJ, Eisel UL, Comijs HC, et al. Neutrophil gelatinase-associated lipocalin: a novel inflammatory marker associated with late-life depression. *J Psychosom Res*. 2013;75:444–50.
71. Tiemeier H, Hofman A, van Tuijl HR, et al. Inflammatory proteins and depression in the elderly. *Epidemiology*. 2003;14:103–7.
72. Fornage M, Chiang YA, O'Meara ES, et al. Biomarkers of inflammation and MRI-defined small vessel disease of the brain: The Cardiovascular Health Study. *Stroke*. 2008;39:1952–9.
73. Raz N, Yang Y, Dahle CL, Land S. Volume of white matter hyperintensities in healthy adults: contribution of age, vascular risk factors, and inflammation-related genetic variants. *Biochim Biophys Acta*. 1822;2012:361–9. *Among 144 healthy older adults, larger white matter hyperintensity volume was associated with age, hypertension, and elevated levels of homocysteine and C-reactive protein, but not with low-density lipoprotein levels. Individuals with genetic variants promoting inflammation had greater volume of white matter hyperintensities than those who did not.*
74. Satizabal CL, Zhu YC, Mazoyer B, et al. Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study. *Neurology*. 2012;78:720–7.
75. van Dijk EJ, Prins ND, Vermeer SE, et al. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. *Circulation*. 2005;112:900–5.
76. Elderkin-Thompson V, Irwin MR, Hellemann G, Kumar A. Interleukin-6 and memory functions of encoding and recall in healthy and depressed elderly adults. *Am J Geriatr Psychiatry*. 2012;20:753–63. *Performance on a memory measure was associated with IL-6 levels among depressed and non-depressed older adults. Older adults with depression had poorer recall than comparisons, independent of IL-6 levels.*
77. Maes M, Leonard BE, Myint AM, et al. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYC ATs), both of which contribute to the onset of depression. *Prog Neuropsychopharmacol Biol Psychiatry*. 2011;35:702–21.
78. O'Connor JC, Andre C, Wang Y, et al. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. *J Neurosci*. 2009;29:4200–9.
79. O'Connor JC, Lawson MA, Andre C, et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. *Mol Psychiatry*. 2009;14:511–22.
80. Stone TW, Behan WM. Interleukin-1beta but not tumor necrosis factor-alpha potentiates neuronal damage by quinolinic acid: protection by an adenosine A2A receptor antagonist. *J Neurosci Res*. 2007;85:1077–85.
81. Koo JW, Duman RS. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. *Proc Natl Acad Sci U S A*. 2008;105:751–6.
82. Leonard BE. Inflammation, depression and dementia: are they connected? *Neurochem Res*. 2007;32:1749–56.
83. Hermida AP, McDonald WM, Steenland K, Levey A. The association between late-life depression, mild cognitive impairment and dementia: is inflammation the missing link? *Expert Rev Neurother*. 2012;12:1339–50.

84. Wirth M, Villeneuve S, Haase CM, et al. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. *JAMA Neurol.* 2013;70:1512–9. *40 % of cognitively normal older adults with no evidence of elevated PiB binding displayed at least one abnormal neurodegenerative biomarker (i.e., hippocampal volume, glucose metabolism, and gray matter thickness). Individuals with abnormal cortical thickness had neurodegenerative abnormalities that were similar to patients with Alzheimer's disease. Greater neurodegenerative abnormalities were associated with poorer memory and executive functioning performance, but not greater PiB binding.*
85. Adams KB, Sanders S, Auth EA. Loneliness and depression in independent living retirement communities: risk and resilience factors. *Aging Ment Health.* 2004;8:475–85.
86. Prince MJ, Harwood RH, Thomas A, Mann AH. A prospective population-based cohort study of the effects of disablement and social milieu on the onset and maintenance of late-life depression. The Gospel Oak Project VII. *Psychol Med.* 1998;28:337–50.
87. Yang Y. How does functional disability affect depressive symptoms in late life? The role of perceived social support and psychological resources. *J Health Soc Behav.* 2006;47:355–72.
88. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. *Lancet Neurol.* 2011;10:819–28.
89. Wirth M, Haase CM, Villeneuve S, et al. Neuroprotective pathways: lifestyle activity, brain pathology, and cognition in cognitively normal older adults. *Neurobiol Aging.* 2014;35:1873–82. *Among 92 cognitively normal older adults, higher lifetime cognitive activity and higher current physical activity were associated with fewer white matter lesions, which were, in turn, associated with a higher composite measure of global integrity and higher cognitive functioning. Higher lifetime cognitive activity predicted lower PiB retention, which moderated the relationship between neural integrity and cognition. It is concluded that lifetime cognitive and current physical activity may decrease the development of dementia by protecting against cerebrovascular and A beta pathology.*
90. Blake H, Mo P, Malik S, Thomas S. How effective are physical activity interventions for alleviating depressive symptoms in older people? A systematic review. *Clin Rehabil.* 2009;23:873–87.
91. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. *J Int Neuropsychol Soc.* 2002;8:448–60.
92. Amieva H, Mokri H, Le Goff M, et al. Compensatory mechanisms in higher-educated subjects with Alzheimer's disease: a study of 20 years of cognitive decline. *Brain.* 2014;137(Pt 4):1167–75. *Over a 20-year period, cognition among 442 people with incident Alzheimer's disease were assessed. Cognitive symptoms emerge up to 16 years preceding conversion to dementia in high and low educated individuals, but among those with low education, more immediately converted to dementia, whereas conversion was slower among those with higher levels of education.*
93. Osone A, Arai R, Hakamada R, Shimoda K. Impact of cognitive reserve on the progression of mild cognitive impairment to Alzheimer's disease in Japan. *Geriatr Gerontol Int.* 2014. doi:10.1111/ggi.12292.
94. Stern Y. Cognitive reserve. *Neuropsychologia.* 2009;47:2015–28.
95. Paulson D, Bowen ME, Lichtenberg PA. Does brain reserve protect older women from vascular depression? *J Gerontol B Psychol Sci Soc Sci.* 2014;69:157–67. *Among 1355 older women, higher level of education and lower cerebrovascular burden were negatively associated with depressive symptoms at baseline, but over six years, the protective effect of education on depressive symptoms decreased.*